drugset / Trial / NCT04912115

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115

Phase 2 Suspended 30 enrolled PharmaTher Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease.

Timeline

Start
2021-10-05
Primary completion
2023-12-30
Completion
2024-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.1 mg/kg Intravenous
Subject Ketamine Small molecule 0.3 mg/kg Intravenous
Comparator Midazolam Small molecule 0.009 mg/kg Intravenous
Comparator Midazolam Small molecule 0.027 mg/kg Intravenous